No Data
No Data
Natera, Inc.'s (NASDAQ:NTRA) Business Is Yet to Catch Up With Its Share Price
It's not a stretch to say that Natera, Inc.'s (NASDAQ:NTRA) price-to-sales (or "P/S") ratio of 11.6x right now seems quite "middle-of-the-road" for companies in the Biotechs industry in the United
These Are the Stocks With the Highest Increase in Short Interest Within Life Sciences and Diagnostics - Baird
Optimistic Outlook for Natera's Growth Potential Based on ALTAIR Trial and MRD Market Opportunity
$1000 Invested In This Stock 5 Years Ago Would Be Worth $4,300 Today
Natera (NASDAQ:NTRA) has outperformed the market over the past 5 years by 19.94% on an annualized basis producing an average annual return of 33.11%. Currently, Natera has a market capitalization of $
Jefferies Maintains Natera(NTRA.US) With Buy Rating, Maintains Target Price $142
Jefferies analyst Tycho Peterson maintains $Natera(NTRA.US)$ with a buy rating, and maintains the target price at $142.According to TipRanks data, the analyst has a success rate of 55.1% and a total a
Analysts Offer Insights on Healthcare Companies: Viking Therapeutics (VKTX), Natera (NTRA) and Argenx Se (ARGX)